By Josh White
Date: Wednesday 08 Jan 2025
(Sharecast News) - Cambridge Cognition announced the use of its 'CANTAB' cognitive assessment product in two phase three clinical trials conducted by Bristol Myers Squibb for 'Cobenfy', a newly FDA-approved treatment for schizophrenia.
By Iain Gilbert
Date: Tuesday 10 Dec 2024
(Sharecast News) - Brain health software group Cambridge Cognition said on Tuesay that full-year revenues were expected to be no less than £10.0m, while adjusted underlying earnings was seen at close to breakeven.
By Josh White
Date: Friday 18 Oct 2024
(Sharecast News) - Cambridge Cognition, a provider of digital solutions for assessing brain health, announced the formal resignation of Dr Matthew Stork as a director of the company and its subsidiaries on Friday.
Currency | UK Pounds |
Share Price | 35.67p |
Change Today | -1.33p |
% Change | -3.60 % |
52 Week High | 52.48 |
52 Week Low | 27.50 |
Volume | 26,357 |
Shares Issued | 41.94m |
Market Cap | £14.96m |
RiskGrade | 282 |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income | ![]() |
---|
Growth |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Strong Buy | 1 |
Buy | 1 |
Neutral | 0 |
Sell | 0 |
Strong Sell | 0 |
Total | 2 |
No dividends found |
Time | Volume / Share Price |
12:49 | 2,500 @ 35.00p |
12:49 | 2,500 @ 35.00p |
12:48 | 2,000 @ 35.00p |
12:45 | 16,293 @ 34.20p |
12:45 | 2,000 @ 36.00p |
You are here: research